---
title: "Varegacestat (AL102) in Desmoid tumors: RINGSIDE part B"
description: "Formulary evidence on Varegacestat (AL102, BMS-986115) in Desmoid tumors: RINGSIDE part B. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 110 evidence topics quoted from 25 sources."
canonical: "https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence/ringside-part-b"
published: "2026-11-18T22:42:04-05:00"
modified: "2026-11-18T22:42:04-05:00"
---

# Varegacestat (AL102) in Desmoid tumors: RINGSIDE part B

<a id="heading-3.1.1"></a>

## 3.1.1 RINGSIDE Part B

<a id="heading-3.1.1.1"></a>

### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

#### Part B primary objective: effect on disease progression

> “Part B (Phase III): To evaluate effects of AL102 on disease progression in subjects with progressing desmoid tumors”

Source: [EU Clinical Trials Information System 2024-515909-26-00](https://euclinicaltrials.eu/ctis-public/view/2024-515909-26-00)

<a id="topic-3.1.1.1-2"></a>

#### Part B secondary objectives: tumor response, quality of life, and safety

> “Part B: To evaluate additional effects of AL102 on tumor response”
> “Part B: To evaluate effects of AL102 on quality of life;”
> “Part B: To evaluate the safety and tolerability of AL102 in subjects with progressing desmoid tumors”
> “OLE: To evaluate the efficacy of AL102 in subjects with progressive desmoid tumors”

Source: [EU Clinical Trials Information System 2024-515909-26-00 API record](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-515909-26-00)

<a id="topic-3.1.1.1-3"></a>

#### Efficacy, safety, and tolerability compared with placebo

> “It is designed to evaluate the efficacy, safety and tolerability of varegacestat compared to placebo in participants with progressing desmoid tumors.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="topic-3.1.1.1-4"></a>

#### Registry summary of the study purpose

> “The current study is designed to evaluate the efficacy and safety of AL102 in patients with progressive desmoid tumors.”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="heading-3.1.1.2"></a>

### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

#### Enrollment period and data cutoff

> “Enrollment: Nov. 15, 2022 ‒ Feb 14, 2024”
> “Data-cutoff date: October 7, 2025”

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

<a id="topic-3.1.1.2-2"></a>

#### Data cutoff of the primary analysis abstract

> “As of Oct 7, 2025, median duration of exposure was 20.3 months (range 0.8 – 34.6) for VAR and 11.1 months (range 0.2 – 34.6) for PBO.”

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)

<a id="topic-3.1.1.2-3"></a>

#### Global conduct and completion of enrollment

> “The Phase 3 portion of RINGSIDE is a registrational, global, double-blind, randomized, placebo-controlled clinical trial, conducted at clinical sites in North America, Europe, Asia and Australia.”
> “Enrollment was completed in February 2024.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="topic-3.1.1.2-4"></a>

#### Registry status and dates for the combined Part A, Part B, and open-label extension record

| Study characteristic | Quoted record |
| --- | --- |
| Overall status | “Active, not recruiting” |
| Study start (actual) | “2021-09-01” |
| Primary completion (actual) | “2025-12-03” |
| Study completion (estimated) | “2026-12” |
| Number of locations | “This study has 53 locations” |

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="topic-3.1.1.2-5"></a>

#### Registry sites by country

| Country | Quoted site names |
| --- | --- |
| United States | “Memorial Sloan Kettering Cancer Center”; “MD Anderson Cancer Center”; “Stanford University Medical Center”; “University of Michigan” |
| Australia | “Peter MacCallum Cancer Centre”; “Adelaide Cancer Centre” |
| Belgium | “Universitaire Ziekenhuizen Leuven” |
| Germany | “Mannheim university medical center” |
| Israel | “Rambam MC”; “Tel Aviv Sourasky Medical Center” |
| Italy | “IRCCS Fondazione Istituto Nazionale dei Tumori” |
| Netherlands | “The Netherlands Cancer Institute” |
| Poland | “Maria Sklodowska-Curie National Research Institute of Oncology” |
| South Korea | “Severance Hospital, Yonsei University Health System” |
| Spain | “Hospital Universitario Fundacion Jimenez Diaz” |
| United Kingdom | “The Royal Marsden Hospital” |

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="topic-3.1.1.2-6"></a>

#### European Union member states, start of trial, and end of recruitment

> “Spain, Germany, Italy, Poland, Netherlands, Belgium”
> “Start of trial 26/01/2022”
> “Netherlands Ongoing, recruitment ended 30/10/2024 11/08/2026 26/01/2022 09/02/2022 14/02/2024”
> “Estimated global end date of the trial:”
> “15/12/2026”

Source: [EU Clinical Trials Information System 2024-515909-26-00](https://euclinicaltrials.eu/ctis-public/view/2024-515909-26-00)

<a id="heading-3.1.1.3"></a>

### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

#### Double-blind, placebo-controlled, randomized phase 3 design with central imaging review

> “RINGSIDE Phase 3 was a double-blind, placebo (PBO)-controlled study in adults with progressing DT per RECIST v1.1 (NCT04871282).”
> “156 pts were randomized 1:1 to once daily oral VAR 1.2 mg (n=79) or PBO (n=77).”
> “Imaging-based tumor response was assessed per RECIST v1.1 by blinded independent central review.”

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)

<a id="topic-3.1.1.3-2"></a>

#### Registry design record

| Study characteristic | Quoted record |
| --- | --- |
| Official title | “RINGSIDE: A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients With Progressing Desmoid Tumors” |
| Study type | “Interventional” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Quadruple” |
| Protocol number | “AL-DES-01” |
| EU trial number | “2024-515909-26-00” |

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="topic-3.1.1.3-3"></a>

#### Stratification by tumor location

> “Randomized 1:1”
> “Stratification factors:”
> “Tumor location (intra- vs. extra-abdominal)”

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

<a id="topic-3.1.1.3-4"></a>

#### Crossover to the open-label extension

> “crossover to OLE from either arm allowed if progressive disease.”

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

> “Cross over to OLE”
> “if progressive disease”
> “if active at primary analysis”

Source: [Immunome topline call presentation (2025)](https://investors.immunome.com/wp-content/uploads/2025/12/Immunome-Topline-Call-Presentation-FINAL.pdf)

> “Participants who progress while on study are eligible to enter an open-label extension whereby they may receive varegacestat at a dose of 1.2 mg once daily until disease progression or unacceptable toxicity.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="topic-3.1.1.3-5"></a>

#### Open-label extension ongoing

> “RINGSIDE includes an open-label extension phase, which is ongoing.”

Source: [Immunome press release, RINGSIDE data at ASCO 2026 (2026)](https://investors.immunome.com/immunome-announces-detailed-phase-3-ringside-data-for-varegacestat-in-adults-with-progressing-desmoid-tumors-at-the-2026-asco-annual-meeting/)

<a id="topic-3.1.1.3-6"></a>

#### Relationship between Part A dose finding and Part B

> “This is a Phase 2/3, randomized study in subjects with progressive desmoid tumors consisting of 2 parts. Phase2/Part A is an open-label, dose regimen finding study; Phase3/Part B is a double blind, placebo-controlled study and Open Label Extension utilizing the dose regimen selected in Phase2/Part A.”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

> “Based on these data and responses demonstrated with other GSIs, Ayala designed a seamless Phase 2/3 study called RINGSIDE to specifically evaluate the activity of varegacestat in participants with progressing desmoid tumors who required therapy.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

> “The RINGSIDE Phase 2 dose-finding study identified the GSI varegacestat 1.2 mg once daily as the dose for Phase 3 study”

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

> “The largest responses were seen with the 1.2-mg once-daily dose, which was selected for the RINGSIDE phase III trial.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.1.3-7"></a>

#### Sponsorship and funding

> “The RINGSIDE study (NCT04871282) was sponsored/funded by Immunome and Ayala Pharmaceuticals, Inc.”

Source: [Kasper et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_3_ESMO-2026_RINGSIDE-B_Topline-T2W_POS_final.pdf)

<a id="heading-3.1.1.4"></a>

### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

#### Key eligibility criteria as presented for the primary analysis

> “Adults with histologically confirmed DT that has progressed in the past 12 months per RECIST 1.1”
> “Treatment-naïve and previously treated patients”
> “Measurable disease”
> “ECOG PS score 0-1”

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

<a id="topic-3.1.1.4-2"></a>

#### Part B inclusion criteria in the registry record

> “≥12 years of age (inclusive) and ≥ 40 kg at the time of signing the ICF.”
> “Histologically confirmed desmoid tumor (aggressive fibromatosis) by local pathologist (prior to informed consent) that has progressed by ≥ 20% as measured by RECIST v1.1 within 12 months of the screening visit scan.”
> “Evidence of measurable disease by CT/MRI scan. Measurable lesions are defined according to RECIST v1.1.”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="topic-3.1.1.4-3"></a>

#### Additional Part B inclusion criteria in the EU trial record

> “Part B: 1. ≥12 years of age (inclusive) in countries which allow participation of adolescents and ≥ 40 kg at the time of signing the ICF.”
> “Part B: Histologically confirmed desmoid tumor (aggressive fibromatosis) by local pathologist (prior to informed consent) that has progressed per RECIST v1.1 (≥20% or new lesion) by investigator within 12 months of the screening visit scan.”
> “Part B: One of the following: • Recurrent/refractory disease following at least one line of therapy (including surgery, radiation, or systemic therapy); OR • Treatment naïve subjects for whom, in the opinion of the investigator, surgery or radiation therapy is not deemed appropriate;”
> “Part B: A desmoid tumor in which continued progressing disease will not result in immediate significant risk to the subject.”
> “Part B: Must be able to swallow whole capsules with no GI condition affecting absorption (not including history of colectomy or proctocolectomy); nasogastric or G-tube administration is not allowed”

Source: [EU Clinical Trials Information System 2024-515909-26-00 API record](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-515909-26-00)

<a id="topic-3.1.1.4-4"></a>

#### Prior treatment status of enrolled participants

> “Enrolled participants were either treatment-naïve with desmoid tumors not amenable to surgery or had refractory or recurrent disease after at least one line of therapy.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="topic-3.1.1.4-5"></a>

#### Exclusion criteria for Parts A and B in the registry record

> “Diagnosed with a malignancy in the past 2 years with some exceptions.”
> “Current or recent (within 2 months of IP administration) GI disease or disorders that increase the risk of diarrhea, such as inflammatory bowel disease and Crohn's disease.”
> “Pregnant or breastfeeding or expecting to conceive children within the projected duration of the study.”
> “Eastern Cooperative Oncology Group (ECOG) performance status ≥2”
> “Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥450 msec.”
> “Any treatments for desmoid tumors within 4 weeks prior to first dose of investigational therapy; subject must have recovered from therapy related toxicity to < CTCAE Grade 2 or clinical baseline.”
> “Systemic therapy including chemotherapy, biologic (anti-neoplastic agent, antibodies), TKIs (e.g., sorafenib, pazopanib, imatinib), hormonal therapy, or investigational therapy”
> “Chronic NSAIDs for the treatment of desmoid tumors within 4 weeks of first dose of IP”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="topic-3.1.1.4-6"></a>

#### Additional Part B exclusion criteria in the EU trial record

> “Part B: History of additional risk factors for TdP”
> “Part B: ECG Exclusions: a. Mean QTcF ≥450 msec; b. Second or third degree AV block”

Source: [EU Clinical Trials Information System 2024-515909-26-00 API record](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-515909-26-00)

<a id="topic-3.1.1.4-7"></a>

#### Open-label extension entry criteria

> “Participated in Part A (including MRI at Week 16) and were still on study at time that Part B/OLE dose selection was made, OR”
> “Participating in Part B and were noted to have radiographic progressive disease by BICR, OR”
> “Are on study treatment (placebo or varegacestat) after completion of Part B”
> “Any participant with an ongoing TEAE (including abnormal laboratory results) from Part A or Part B that requires discontinuation from the study, will not be eligible to enter the open-label extension.”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="heading-3.1.1.5"></a>

### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

#### Randomized treatment arms

> “156 pts were randomized 1:1 to once daily oral VAR 1.2 mg (n=79) or PBO (n=77).”

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)

| Arm | Quoted registry description |
| --- | --- |
| Part B AL102 | “AL102, recommended dose regimen from Part A, 1.2 mg daily” |
| Part B placebo | “Placebo to match recommended dose regimen from Part A” |
| Open-label extension | “AL102, recommended dose regimen from Part A, 1.2 mg daily” |
| Study drug | “AL102 is an inhibitor of gamma secretase-mediated Notch signaling.” |

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="topic-3.1.1.5-2"></a>

#### Treatment duration

> “A total of 156 patients were randomized to receive varegacestat 1.2 mg daily or placebo until disease progression or death”

Source: [Immunome press release, RINGSIDE data at ASCO 2026 (2026)](https://investors.immunome.com/immunome-announces-detailed-phase-3-ringside-data-for-varegacestat-in-adults-with-progressing-desmoid-tumors-at-the-2026-asco-annual-meeting/)

<a id="topic-3.1.1.5-3"></a>

#### Dose levels used for dose reduction

> “Median Time to First Dose Reduction”
> “to 0.9 mg (n=60): 3.7 (IQR 1.8, 8.3) months”
> “to 0.6 mg (n=36): 7.3 (IQR 3.0, 12.5) months”

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

<a id="topic-3.1.1.5-4"></a>

#### Capsule formulation

> “Part B: Must be able to swallow whole capsules with no GI condition affecting absorption (not including history of colectomy or proctocolectomy); nasogastric or G-tube administration is not allowed”

Source: [EU Clinical Trials Information System 2024-515909-26-00 API record](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-515909-26-00)

<a id="topic-3.1.1.5-5"></a>

#### Prohibited prior desmoid tumor therapy before the first dose

> “Locoregional tumor directed therapies such as major surgery, radiation, radiofrequency ablation, or cryosurgery”
> “Chronic NSAIDs for the treatment of desmoid tumors within 4 weeks of first dose of IP”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="heading-3.1.1.6"></a>

### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

#### 3.1.1.6.1 Rationale for Using Progression-free Survival as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

##### Primary endpoint: progression-free survival by blinded independent central review per RECIST v1.1

> “PFS as defined as the time from randomization until the date of assessment of progression as assessed by BICR based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or death by any cause”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

> “PFS was defined as time from randomization until the date of assessment of radiographic progression as assessed Blinded Independent Central Review (BICR) based on RECIST v1.1”
> “Progression was defined as ≥20% increase per RECIST v1.1”

Source: [Immunome topline call presentation (2025)](https://investors.immunome.com/wp-content/uploads/2025/12/Immunome-Topline-Call-Presentation-FINAL.pdf)

<a id="topic-3.1.1.6.1-2"></a>

##### Primary endpoint in the EU trial record

> “Part B: Progression free survival”

Source: [EU Clinical Trials Information System 2024-515909-26-00 API record](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-515909-26-00)

<a id="topic-3.1.1.6.1-3"></a>

##### Design consistent with prior registrational trials

> “Design consistent with prior registrational trials”

Source: [Immunome topline call presentation (2025)](https://investors.immunome.com/wp-content/uploads/2025/12/Immunome-Topline-Call-Presentation-FINAL.pdf)

<a id="topic-3.1.1.6.1-4"></a>

##### Precedent: progression-free survival as the primary end point of DeFi

> “The DeFi (Desmoid Fibromatosis) trial was a phase 3, international, double-blind, randomized, placebo-controlled trial to determine the efficacy and safety of nirogacestat in patients 18 years of age or older with a histologically confirmed diagnosis of progressing desmoid tumors (defined as ≥20% progression according to the Response Evaluation Criteria in Solid Tumors [RECIST], version 1.1, within 12 months before screening).”
> “The primary end point was progression-free survival, defined as the time from randomization until the date of imaging-based or clinical progression or death.”
> “Both imaging-based and clinical progression were confirmed by blinded independent central review.”

Source: [Gounder et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11225596/)

<a id="topic-3.1.1.6.1-5"></a>

##### Precedent: progression-free survival as the major efficacy outcome in the nirogacestat label

> “The major efficacy outcome was progression-free survival (PFS) based on RECIST v1.1 as assessed by blinded independent central review or on clinical progression by the investigator (and confirmed by independent review).”
> “Crossover was permitted at the time of radiographic progression.”

Source: [SpringWorks OGSIVEO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217677s009lbl.pdf)

<a id="topic-3.1.1.6.1-6"></a>

##### Precedent: progression-free survival as the primary end point of the sorafenib phase 3 trial

> “The primary end point was progression-free survival, as determined by the treating physicians in accordance with RECIST, version 1.1.”

Source: [Gounder et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6447029/)

<a id="topic-3.1.1.6.1-7"></a>

##### Variable natural history and the need for a placebo control

> “Interpretation of the data is challenging, given the unpredictable natural history of the condition. Desmoid tumors can show rapid growth followed by periods of stabilization, spontaneous regression, or subsequent growth phases.”

Source: [Gounder et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6447029/)

> “In a phase 3 trial of sorafenib involving adults with desmoid tumors, progression-free survival was significantly longer with sorafenib than with placebo (P<0.001); however, 20% of the participants in the placebo group had an objective response, a finding that highlights the need for a placebo control in this population.”

Source: [Gounder et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11225596/)

> “The ORR was 33% for sorafenib; however, the placebo arm ORR was as high as 20% demonstrating spontaneous regression and giving useful information on the natural history of this disease.”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

> “Spontaneous regressions are observed in as many as 20%–30% of cases”

Source: [Kasper et al. (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5834048/)

<a id="topic-3.1.1.6.1-8"></a>

##### Limitations of RECIST and progression-free survival in desmoid tumors

> “RECIST does not robustly identify all clinically relevant responses, though the majority of prospective trials report efficacy using RECIST.”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

> “The dimension-based RECIST is currently employed within clinical trials”

Source: [Kasper et al. (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5834048/)

> “Existing clinical trial endpoints such as the Response Evaluation Criteria in Solid Tumors (version 1.1) and progression-free survival are inadequate in capturing treatment efficacy.”
> “These surrogate endpoints for overall survival may not be appropriate for a disease with low mortality and importantly fail to capture whether treatments truly improve symptoms and/or affect daily living.”

Source: [Gounder et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6980244/)

<a id="topic-3.1.1.6.1-9"></a>

##### Alpha-controlled key secondary endpoints

> “The primary endpoint was progression-free survival (PFS).”
> “Alpha-controlled secondary endpoints were confirmed objective response rate (ORR), change in tumor volume (TV) at Week 24, and change in patient-reported worst pain intensity (WPI) at Week 12.”

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)

> “Statistically controlled secondary endpoints were confirmed ORR using RECIST v1.1 and change in tumor volume at week 24, both determined by blinded independent central review, as well as change in pain intensity at week 12 as determined using a patient-reported outcome instrument.”
> “Additional secondary endpoints included duration of response, best reduction in tumor volume, patient-reported outcomes, and safety and tolerability.”

Source: [Immunome press release, RINGSIDE data at ASCO 2026 (2026)](https://investors.immunome.com/immunome-announces-detailed-phase-3-ringside-data-for-varegacestat-in-adults-with-progressing-desmoid-tumors-at-the-2026-asco-annual-meeting/)

<a id="topic-3.1.1.6.1-10"></a>

##### Key secondary endpoint: objective response rate by blinded independent central review per RECIST v1.1

> “Defined as the proportion of subjects with confirmed ORR (complete response [CR] and partial response [PR]) by BICR based on RECIST v1.1.”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="topic-3.1.1.6.1-11"></a>

##### Key secondary endpoint: tumor volume at Week 24 by T2-weighted MRI or CT

> “Change from baseline at Week 24 in estimated tumor volume measured by T2 weighted (T2W) MRI or CT by BICR”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

> “Measured by T2 weighted MRI or CT per BICR”

Source: [Immunome topline call presentation (2025)](https://investors.immunome.com/wp-content/uploads/2025/12/Immunome-Topline-Call-Presentation-FINAL.pdf)

<a id="topic-3.1.1.6.1-12"></a>

##### Rationale for volumetric and T2-weighted MRI assessment

> “T2-weighted (T2W) signal intensity and tumor volume on MRI may be more sensitive than RECIST for assessing treatment effect in desmoid tumors (DTs)”

Source: [Gounder et al. (2025)](https://immunome.com/wp-content/uploads/2025/08/ASCO-2025-RINGSIDE-A-T2W-Poster.pdf)

> “The retrospective study also highlighted that RECIST may underestimate efficacy and that a better criterion may be magnetic resonance imaging (MRI) T2-weighted signal intensity, an imaging biomarker that signifies a biologic transformation from a cellular tumor to a collagenous scar.”
> “Exploratory imaging end points included a comparison of RECIST measurements with total tumor volume and MRI T2-weighted signal intensity in patients.”

Source: [Gounder et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6447029/)

> “MRI surveillance has been used to assess response to treatment with a decrease in T2W signal and lesion size”

Source: [Kasper et al. (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5834048/)

<a id="topic-3.1.1.6.1-13"></a>

##### Tumor assessments by blinded independent central review in the primary analysis poster

> “Tumor Assessments by BICR”
> “Response per RECIST v1.1”
> “Tumor volume (TV)”
> “T2W signal intensity”
> “Findings add to a growing body of work showing T2W may play a role in evaluating treatment response in DT.”

Source: [Kasper et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_3_ESMO-2026_RINGSIDE-B_Topline-T2W_POS_final.pdf)

<a id="topic-3.1.1.6.1-14"></a>

##### Key secondary endpoint: GODDESS worst pain intensity at Week 12

> “Change from baseline to Week 12 in the worst pain intensity (WPI) using GOunder/Desmoid Tumor Research Foundation (DTRF) DEsmoid Symptom Scale and Impact Scale (GODDESS) Desmoid Tumor Symptom Scale (DTSS)”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

> “Measured using Desmoid Tumor Symptom Scale Item 1 from the GOunder/Desmoid Tumor Research Foundation Desmoid Tumor Symptom/Impact Scale (GODDESS)”

Source: [Immunome topline call presentation (2025)](https://investors.immunome.com/wp-content/uploads/2025/12/Immunome-Topline-Call-Presentation-FINAL.pdf)

<a id="topic-3.1.1.6.1-15"></a>

##### GODDESS scoring and administration in RINGSIDE

> “Higher Scores = Worse Symptoms; scored on 0 to 10 scale”
> “Domains and Items scored 0 (no symptoms) to 10 (worse symptoms imaginable)”
> “Completed as a daily diary for 7 days (scores averaged over the 7 days), at baseline and every 4 weeks”
> “Clinically meaningful thresholds were derived from the RINGSIDE population”

Source: [van der Graaf et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_1_ESMO_BriefOralPres_V1.0_21-Sept-2026.pdf)

<a id="topic-3.1.1.6.1-16"></a>

##### Rationale for GODDESS as a disease-specific endpoint

> “This study was designed to develop a novel clinical trial endpoint by capturing patient-reported outcomes (PROs).”
> “This is the first disease-specific PRO instrument developed for desmoid tumors.”

Source: [Gounder et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6980244/)

> “GODDESS© was found to be reliable, valid, responsive, and interpretable as a clinical trial endpoint in the pooled sample of DT/AF patients.”

Source: [Gounder et al. (2023c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10474203/)

<a id="topic-3.1.1.6.1-17"></a>

##### Exploratory patient-reported endpoints: GODDESS symptom scores and PROMIS Physical Function

> “Select PRO Exploratory Endpoints:”
> “Change from baseline in pain and DT symptoms (GODDESS)”
> “Change from baseline in Physical Functioning (PROMIS Physical Functioning 10a)”
> “(Pain intensity, fatigue, swelling, muscle weakness, difficulty moving)”
> “Higher Scores = Better Function”
> “Items scored on a scale of 1 (cannot do) to 5 (can do without any difficulty/ not impacted)”
> “Completed once at baseline and every 4 weeks”

Source: [van der Graaf et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_1_ESMO_BriefOralPres_V1.0_21-Sept-2026.pdf)

<a id="topic-3.1.1.6.1-18"></a>

##### Other Part B secondary endpoints in the registry record

| Endpoint | Quoted registry definition |
| --- | --- |
| Duration of response | “Defined by the time from confirmed CR or PR (by BICR based on RECIST v1.1) until the earlier of the first documentation of disease progression or death from any cause” |
| Progression-free survival including clinical progression | “Defined as the time from randomization until the date of radiographic progression as assessed by BICR or clinical progression as assessed by the investigator or death by any cause” |
| Adverse events | “Evaluation of the safety and tolerability of AL102 in subjects with progressing desmoid tumors as defined by the frequency and severity of TEAEs and SAEs” |
| Time to treatment discontinuation | “Evaluation of the safety and tolerability of AL102 in subjects with progressing desmoid tumors as defined by the time to treatment discontinuation due to TEAE” |

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="topic-3.1.1.6.1-19"></a>

##### Part B secondary end points in the EU trial record

> “Part B: proportion of subjects with confirmed ORR”
> “Part B: duration of response”
> “Part B: PFS as defined as the time from randomization until the date of radiographic progression by BICR or clinical progression”
> “Part B: Change from baseline at Week 24 in estimated tumor volume”
> “Part B: Change from baseline to Week 12 in the worst pain intensity (WPI)”
> “Part B: frequency and severity of TEAEs and SAEs”
> “Part B: time to treatment discontinuation due to TEAE”

Source: [EU Clinical Trials Information System 2024-515909-26-00 API record](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-515909-26-00)

<a id="topic-3.1.1.6.1-20"></a>

##### Registry secondary outcome measures without Week 24 and Week 12 time points, February 2026, superseded in June 2026

> “Viewing V37 (2026-02-03)”
> “Change from baseline in estimated tumor volume measured by T2 weighted (T2W) MRI or CT by BICR (based on RECIST v1.1)”
> “Change from baseline in pain assessment using GOunder/Desmoid Tumor Research Foundation (DTRF) DEsmoid Symptom Scale and Impact Scale (GODDESS) Desmoid Tumor Symptom Scale (DTSS)”

Source: [ClinicalTrials.gov NCT04871282 version 37](https://clinicaltrials.gov/study/NCT04871282?tab=history&a=37)

<a id="topic-3.1.1.6.1-21"></a>

##### Registry secondary outcome measures with PROMIS, EQ-5D, and Brief Pain Inventory, November 2024, superseded in May 2025

> “Viewing V35 (2024-11-06)”
> “36 2025-05-31 Study Status Oversight Study Design Arms and Interventions Outcome Measures Contacts/Locations”
> “Change from baseline in quality of life as measured by GOunder/Desmoid Tumor Research Foundation (DTRF) DEsmoid Symptom Scale and Impact Scale (GODDESS)”
> “Change from baseline in quality of life as measured by Patient-reported outcomes measurement information system (PROMIS) Physical Function”
> “Change from baseline in quality of life as measured by EuroQol 5-dimensional questionnaire(EQ-5D)”
> “Change from baseline in pain assessment using brief pain inventory (BPI) short form”

Source: [ClinicalTrials.gov NCT04871282 version 35](https://clinicaltrials.gov/study/NCT04871282?tab=history&a=35)

<a id="heading-3.1.1.7"></a>

### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

#### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

##### Participants randomized in Part B

> “156 pts were randomized 1:1 to once daily oral VAR 1.2 mg (n=79) or PBO (n=77).”

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)

> “One hundred fifty-six participants with histologically confirmed desmoid tumors with progressive disease (defined as tumor growth of at least 20% within the past 12 months as measured by RECIST v1.1) were enrolled.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="topic-3.1.1.7.1-2"></a>

##### Participants analyzed for progression-free survival

> “No. of Patients”
> “No. of Events”

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

| Arm | Participants analyzed | Events |
| --- | --- | --- |
| Varegacestat | “79” | “7” |
| Placebo | “77” | “29” |

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

<a id="topic-3.1.1.7.1-3"></a>

##### Registry enrollment for the combined record

> “Enrollment (Actual)”
> “198”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="topic-3.1.1.7.1-4"></a>

##### Part A enrollment within the combined registry record

> “In total, 42 participants enrolled in the randomized trial (14 per dose arm).”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.1.7.1-5"></a>

##### Planned enrollment in the registry record, November 2024, superseded in May 2025

> “Viewing V35 (2024-11-06)”
> “192 [Estimated]”

Source: [ClinicalTrials.gov NCT04871282 version 35](https://clinicaltrials.gov/study/NCT04871282?tab=history&a=35)

<a id="heading-3.1.1.7.2"></a>

#### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

##### Intention-to-treat population defined as all participants who received at least one dose

> “Population: all participants who received ≥1 dose of study drug (i.e., the intention-to-treat population).”

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

<a id="topic-3.1.1.7.2-2"></a>

##### Hazard ratio model stratified by tumor location

> “Hazard ratio estimated from Cox proportional hazards model stratified by tumor location (intra-abdominal vs extra-abdominal)”
> “Post-hoc subgroup analysis to evaluate patients with poor prognosis”

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

<a id="topic-3.1.1.7.2-3"></a>

##### Hierarchy of alpha-controlled and non-alpha-controlled endpoints

> “Alpha-controlled secondary endpoints were confirmed objective response rate (ORR), change in tumor volume (TV) at Week 24, and change in patient-reported worst pain intensity (WPI) at Week 12.”
> “Not alpha-controlled endpoint.”
> “LS, least square; SE, standard error.”

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)

<a id="topic-3.1.1.7.2-4"></a>

##### Patient-reported outcome analyses in the intention-to-treat population with mixed models for repeated measures

> “Analyses on ITT population; symptoms at baseline were not an enrollment criterion”
> “Least-square (LS) means derived from mixed model for repeated measures (MMRM)”

Source: [van der Graaf et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_1_ESMO_BriefOralPres_V1.0_21-Sept-2026.pdf)

<a id="topic-3.1.1.7.2-5"></a>

##### Descriptive analysis of RECIST diameters, tumor volume, and T2-weighted signal

> “Descriptive Analysis”
> “Change from baseline in RECIST sum of diameters (SOD), TV, and T2W signal intensity”

Source: [Kasper et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_3_ESMO-2026_RINGSIDE-B_Topline-T2W_POS_final.pdf)

<a id="topic-3.1.1.7.2-6"></a>

##### Kaplan-Meier estimation of duration of response

> “Duration of response (months), median (95% CI)”
> “Kaplan-Meier estimate. DOR, duration of response; RECIST, Response Evaluation Criteria in Solid Tumors, version 1.1”

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

<a id="heading-3.1.1.8"></a>

### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

#### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

##### Randomized participants by arm

> “156 pts were randomized 1:1 to once daily oral VAR 1.2 mg (n=79) or PBO (n=77).”

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)

<a id="topic-3.1.1.8.1-2"></a>

##### Enrollment period and data cutoff

> “Enrollment: Nov. 15, 2022 ‒ Feb 14, 2024”
> “Data-cutoff date: October 7, 2025”

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

<a id="topic-3.1.1.8.1-3"></a>

##### Duration of exposure by arm

> “As of Oct 7, 2025, median duration of exposure was 20.3 months (range 0.8 – 34.6) for VAR and 11.1 months (range 0.2 – 34.6) for PBO.”

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)

> “Varegacestat 20 months | Placebo 11 months”

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

> “The median exposure was 20.3 months for patients receiving varegacestat vs. 11.1 months for placebo.”

Source: [Immunome press release, RINGSIDE data at ASCO 2026 (2026)](https://investors.immunome.com/immunome-announces-detailed-phase-3-ringside-data-for-varegacestat-in-adults-with-progressing-desmoid-tumors-at-the-2026-asco-annual-meeting/)

<a id="topic-3.1.1.8.1-4"></a>

##### Discontinuation due to adverse events by arm

> “16 (20%) VAR pts and 5 (7%) PBO pts discontinued due to AEs.”

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)

> “Discontinuation Due to AEs: Varegacestat 20% | Placebo 6%”

Source: [Kasper et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_3_ESMO-2026_RINGSIDE-B_Topline-T2W_POS_final.pdf)

<a id="topic-3.1.1.8.1-5"></a>

##### Treatment duration and absence of progressive disease with varegacestat

> “Median treatment duration: 20 months”
> “Note: No varegacestat participants had progressive disease (PD).”

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

<a id="topic-3.1.1.8.1-6"></a>

##### Open-label extension ongoing

> “RINGSIDE includes an open-label extension phase, which is ongoing.”

Source: [Immunome press release, ESMO 2026 data (2026)](https://investors.immunome.com/immunome-presents-additional-clinical-data-for-varegacestat-in-desmoid-tumors-at-esmo-2026/)

<a id="heading-3.1.1.8.2"></a>

#### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

##### Balance between arms

> “Demographics and disease characteristics were balanced between treatment arms.”

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)

<a id="topic-3.1.1.8.2-2"></a>

##### Demographics, tumor characteristics, and prior therapy

| Characteristic, n (%) | Varegacestat (n=79) | Placebo (n=77) |
| --- | --- | --- |
| Median age (range), years | “42.0 (18–66)” | “39.0 (20–69)” |
| Male | “26 (32.9)” | “29 (37.7)” |
| Female | “53 (67.1)” | “48 (62.3)” |
| Premenopausal | “36 (45.6)” | “38 (49.4)” |
| Target tumor location: extra-abdominal | “60 (75.9)” | “49 (63.6)” |
| Target tumor location: intra-abdominal | “19 (24.1)” | “28 (36.4)” |
| Medical history of FAP | “7 (8.9)” | “8 (10.4)” |
| Median target tumor size per RECIST (range), mm | “75.1 (18.0, 244.9)” | “84.8 (21.3, 666.3)” |
| Any prior therapy | “52 (65.8)” | “60 (77.9)” |
| Prior surgery | “24 (30.4)” | “33 (42.9)” |
| Prior radiation therapy | “8 (10.1)” | “12 (15.6)” |
| Prior systemic therapy | “43 (54.4)” | “46 (59.7)” |
| Prior systemic therapies: 0 lines | “36 (45.6)” | “31 (40.3)” |
| Prior systemic therapies: 1 line | “25 (31.6)” | “22 (28.6)” |
| Prior systemic therapies: 2 or more lines | “18 (22.8)” | “24 (31.2)” |

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

<a id="topic-3.1.1.8.2-3"></a>

##### Definition of prior systemic therapy and rounding

> “Includes chemotherapy, tyrosine kinase inhibitors, and hormonal therapy”
> “Percentages may not total 100 because of rounding.”

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

<a id="topic-3.1.1.8.2-4"></a>

##### Premenopausal women as a proportion of female participants

| Characteristic | Varegacestat (n=79) | Placebo (n=77) |
| --- | --- | --- |
| Premenopausal, n/N of female participants (%) | “36/53 (67.9)” | “38/48 (79.2)” |

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

<a id="topic-3.1.1.8.2-5"></a>

##### Baseline worst pain intensity

> “At baseline, the mean WPI score was 4.43 for varegacestat and 4.94 for placebo.”
> “Approximately 80% had a score of ≥2.”

Source: [van der Graaf et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_1_ESMO_BriefOralPres_V1.0_21-Sept-2026.pdf)

<a id="topic-3.1.1.8.2-6"></a>

##### Baseline symptom burden and physical function

> “Average baseline score across arms was approximately 4 indicating moderate symptom burden.”
> “A T-score of 50 reflects the average level of physical functioning in a general population; average baseline score across arms was approximately 45, indicating mild functional impairment.”

Source: [van der Graaf et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_1_ESMO_BriefOralPres_V1.0_21-Sept-2026.pdf)

<a id="heading-3.1.1.8.3"></a>

#### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

##### Primary endpoint: progression-free survival

> “VAR demonstrated significantly better PFS compared with PBO (hazard ratio [HR]: 0.16 [95% CI: 0.07, 0.38; P<0.0001]).”

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)

<a id="topic-3.1.1.8.3-2"></a>

##### RINGSIDE phase 3 trial outcomes table

| Outcome | VAR (n=79) | PBO (n=77) | HR (95% CI) or Difference; P value |
| --- | --- | --- | --- |
| Median PFS (95% CI), radiographic, months | “NE (NE, NE)” | “24.9 (13.8, NE)” | “0.16 (0.07, 0.38); P<0.0001” |
| Confirmed ORR, n (%) | “44 (55.7)” | “7 (9.1)” | “P<0.0001” |
| TV change (cm3) at Week 24, LS mean (SE) | “-109.6 (40.64)” | “122.8 (42.72)” | “-232.4 (57.39); P<0.0001” |
| WPI (pain) change at Week 12, LS mean (SE) | “-2.24 (0.27)” | “0.18 (0.27)” | “-2.42 (0.37); P<0.0001” |
| Median best % change in TV (not alpha-controlled) | “-83.4” | “11.3” | |

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)

<a id="topic-3.1.1.8.3-3"></a>

##### Progression-free survival events and median, ASCO 2026 presentation

| Arm | No. of patients | No. of events | Median PFS (95% CI) (mo) |
| --- | --- | --- | --- |
| Varegacestat | “79” | “7” | “NE (NE, NE)” |
| Placebo | “77” | “29” | “24.87 (13.80, NE)” |

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

> “0.16 (95% CI, 0.07, 0.38) P<0.0001”
> “84% reduction in the risk of radiographic disease progression or death with varegacestat vs. placebo”

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

<a id="topic-3.1.1.8.3-4"></a>

##### Progression-free survival hazard ratio with confidence limits to three decimal places

> “The trial met its primary endpoint of improving progression-free survival, demonstrating a statistically significant and clinically meaningful improvement vs. placebo, with an 84% reduction in the risk of disease progression or death (hazard ratio (HR) = 0.16, 95% CI: 0.071, 0.375; p<0.0001).”

Source: [Immunome press release, RINGSIDE topline results (2025)](https://investors.immunome.com/immunome-announces-positive-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors/)

> “Progression-Free Survival: HR 0.16; 95% CI: 0.071, 0.375; p < 0.0001”

Source: [Immunome topline call presentation (2025)](https://investors.immunome.com/wp-content/uploads/2025/12/Immunome-Topline-Call-Presentation-FINAL.pdf)

> “Progression-Free Survival: HR 0.16; 95% CI: 0.071, 0.375; p < 0.0001”

Source: [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf)

<a id="topic-3.1.1.8.3-5"></a>

##### Landmark progression-free survival rates at 1 and 2 years

| Arm | 1 Year | 2 Years |
| --- | --- | --- |
| Varegacestat | “94% (95% CI: 85–98%)” | “89% (95% CI: 78–95%)” |
| Placebo | “66% (95% CI: 52–76%)” | “57% (95% CI: 43–69%)” |

Source: [Kasper et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_3_ESMO-2026_RINGSIDE-B_Topline-T2W_POS_final.pdf)

<a id="topic-3.1.1.8.3-6"></a>

##### Progression-free survival subgroups

> “PFS consistently favored VAR in all subgroups analyzed.”

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)

> “Post-hoc subgroup analysis to evaluate patients with poor prognosis”
> “Hazard ratio estimated from Cox proportional hazards model stratified by tumor location (intra-abdominal vs extra-abdominal)”

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

> “PFS consistently favored varegacestat in all subgroups analyzed”
> “Male/female”
> “Age ≤30 / >30 years”
> “Baseline tumor size >10 / ≤10 cm”
> “Prior systemic DT therapy (yes/no)”

Source: [Kasper et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_3_ESMO-2026_RINGSIDE-B_Topline-T2W_POS_final.pdf)

> “The PFS benefit observed with varegacestat vs. placebo was consistent across key subgroups, including tumor location, baseline tumor size, patient age and prior systemic desmoid tumor therapy.”

Source: [Immunome press release, RINGSIDE data at ASCO 2026 (2026)](https://investors.immunome.com/immunome-announces-detailed-phase-3-ringside-data-for-varegacestat-in-adults-with-progressing-desmoid-tumors-at-the-2026-asco-annual-meeting/)

<a id="topic-3.1.1.8.3-7"></a>

##### Key secondary endpoint: confirmed objective response rate and complete responses

> “ORR was significantly better with VAR vs PBO (55.7% vs 9.1%; P<0.0001), with 3 CRs in the VAR arm and 1 CR in the PBO arm.”
> “Median duration of response was not reached in either arm.”

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)

<a id="topic-3.1.1.8.3-8"></a>

##### Objective response, time to response, and best overall response

| Outcome | Varegacestat (n=79) | Placebo (n=77) |
| --- | --- | --- |
| Objective response rate, n (%) [95% CI] | “44 (55.7) [44.1, 66.9]” | “7 (9.1) [3.7, 17.8]” |
| Time to objective response (months), median (range) | “8.2 (2.6–28.0)” | “16.7 (8.1–30.2)” |
| Duration of response (months), median (95% CI), Kaplan-Meier estimate | “NE (NE, NE)” | “NE (NE, NE)” |
| Complete response (CR) | “3 (3.8)” | “1 (1.3)” |
| Partial response (PR) | “41 (51.9)” | “6 (7.8)” |
| Stable disease (SD) | “32 (40.5)” | “59 (76.6)” |
| Progressive disease (PD) | “0” | “10 (13.0)” |
| Not available | “3 (3.8)” | “1 (1.3)” |

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

<a id="topic-3.1.1.8.3-9"></a>

##### Objective response rate rounded to whole percentages

> “The confirmed objective response rate (ORR) based on RECIST v1.1 was 56% with varegacestat vs. 9% with placebo (p<0.0001), as assessed by blinded independent central review.”

Source: [Immunome press release, RINGSIDE topline results (2025)](https://investors.immunome.com/immunome-announces-positive-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors/)

<a id="topic-3.1.1.8.3-10"></a>

##### Time to response among responders

> “Among responders treated with varegacestat, median time to response was 8.2 months (range: 2.6-28.0 months) vs. 16.7 months (range: 8.1-30.2 months) for responders receiving placebo.”

Source: [Immunome press release, RINGSIDE data at ASCO 2026 (2026)](https://investors.immunome.com/immunome-announces-detailed-phase-3-ringside-data-for-varegacestat-in-adults-with-progressing-desmoid-tumors-at-the-2026-asco-annual-meeting/)

<a id="topic-3.1.1.8.3-11"></a>

##### Key secondary endpoint: change in tumor volume at Week 24

> “Varegacestat: -109.6 (40.64)”
> “Placebo +122.8 (42.72)”
> “Difference: −232.4 (57.39), P<0.0001”
> “Least-squares mean (standard error)”

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

<a id="topic-3.1.1.8.3-12"></a>

##### Tumor volume measured by T2-weighted MRI or CT

> “Measured by T2 weighted MRI or CT per BICR”

Source: [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf)

<a id="topic-3.1.1.8.3-13"></a>

##### Median best percent change in tumor volume

> “Median best percent change: −83% (range: −100 to 55)”
> “Median best percent change: +11% (range: −100 to 199)”

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

> “In an exploratory analysis, varegacestat demonstrated a median best change in tumor volume of -83% vs. +11% with placebo, as assessed by blinded independent central review.”

Source: [Immunome press release, RINGSIDE topline results (2025)](https://investors.immunome.com/immunome-announces-positive-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors/)

<a id="topic-3.1.1.8.3-14"></a>

##### T2-weighted MRI signal intensity: descriptive analysis

> “T2-Weighted Signal Intensity Reduction”
> “Median best percent change: varegacestat -100% vs placebo -12%”
> “Change from baseline in RECIST sum of diameters (SOD), TV, and T2W signal intensity”

Source: [Kasper et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_3_ESMO-2026_RINGSIDE-B_Topline-T2W_POS_final.pdf)

<a id="heading-3.1.1.8.4"></a>

#### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.1.8.4-1"></a>

##### Key secondary endpoint: GODDESS worst pain intensity at Week 12

> “Varegacestat: −2.24 (0.27)”
> “Placebo: +0.18 (0.27)”
> “Difference: −2.42 (0.37), P<0.0001”
> “Clinically significant difference (>2 points) in favor of varegacestat as early as first evaluation at Week 4”
> “Assessed with the Gounder/Desmoid Tumor Research Foundation Desmoid Tumor Symptom/Impact Scale”

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

> “At week 12, patients treated with varegacestat experienced a mean change from baseline of -2.24 (standard error [SE]: 0.27) compared with +0.18 (SE: 0.27) for patients receiving placebo, for a treatment difference of -2.42 (SE: 0.37; p<0.0001).”

Source: [Immunome press release, RINGSIDE data at ASCO 2026 (2026)](https://investors.immunome.com/immunome-announces-detailed-phase-3-ringside-data-for-varegacestat-in-adults-with-progressing-desmoid-tumors-at-the-2026-asco-annual-meeting/)

<a id="topic-3.1.1.8.4-2"></a>

##### Exploratory PRO endpoints: GODDESS and PROMIS Physical Function 10a

> “Select PRO Exploratory Endpoints:”
> “Change from baseline in pain and DT symptoms (GODDESS)”
> “Change from baseline in Physical Functioning (PROMIS Physical Functioning 10a)”
> “Completed as a daily diary for 7 days (scores averaged over the 7 days), at baseline and every 4 weeks”
> “Completed once at baseline and every 4 weeks”
> “Analyses on ITT population; symptoms at baseline were not an enrollment criterion”
> “Clinically meaningful thresholds were derived from the RINGSIDE population”

Source: [van der Graaf et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_1_ESMO_BriefOralPres_V1.0_21-Sept-2026.pdf)

<a id="topic-3.1.1.8.4-3"></a>

##### GODDESS DTSS pain domain score: least-squares mean difference by week

| Analysis visit | Varegacestat participants with data | Placebo participants with data | Difference, varegacestat vs placebo |
| --- | --- | --- | --- |
| Week 12 | “52” | “55” | “Diff: -2.32” |
| Week 24 | “47” | “43” | “Diff: -2.02” |
| Week 48 | “37” | “27” | “Diff: -2.70” |

Source: [van der Graaf et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_1_ESMO_BriefOralPres_V1.0_21-Sept-2026.pdf)

> “Change in DTSS Pain Domain Score† (worst pain, dull pain, shooting pain)”
> “clinically meaningful improvement = -1.62”
> “Nominal p <0.05”
> “Least-square (LS) means derived from mixed model for repeated measures (MMRM)”

Source: [van der Graaf et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_1_ESMO_BriefOralPres_V1.0_21-Sept-2026.pdf)

<a id="topic-3.1.1.8.4-4"></a>

##### GODDESS DTSS TSS-5 symptom score: least-squares mean difference by week

| Analysis visit | Varegacestat participants with data | Placebo participants with data | Difference, varegacestat vs placebo |
| --- | --- | --- | --- |
| Week 12 | “52” | “55” | “Diff: -1.46” |
| Week 24 | “47” | “43” | “Diff: -1.43” |
| Week 48 | “37” | “27” | “Diff: -2.09” |

Source: [van der Graaf et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_1_ESMO_BriefOralPres_V1.0_21-Sept-2026.pdf)

> “Pain intensity, fatigue, swelling, muscle weakness, difficulty moving”
> “clinically meaningful improvement = -1.16.”

Source: [van der Graaf et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_1_ESMO_BriefOralPres_V1.0_21-Sept-2026.pdf)

<a id="topic-3.1.1.8.4-5"></a>

##### GODDESS TSS-5 symptom score at week 48, ESMO 2026 press release

> “At week 48, patients treated with varegacestat had a least-squares mean change from baseline in the GODDESS TSS-5 symptom score of -1.50 vs. +0.59 for patients receiving placebo, with lower scores indicating lower symptom burden.”

Source: [Immunome press release, ESMO 2026 data (2026)](https://investors.immunome.com/immunome-presents-additional-clinical-data-for-varegacestat-in-desmoid-tumors-at-esmo-2026/)

<a id="topic-3.1.1.8.4-6"></a>

##### PROMIS Physical Function 10a T-score: least-squares mean difference by week

| Analysis visit | Varegacestat participants with data | Placebo participants with data | Difference, varegacestat vs placebo |
| --- | --- | --- | --- |
| Week 12 | “54” | “60” | “Diff: +3.13” |
| Week 24 | “47” | “45” | “Diff: +5.84” |
| Week 48 | “37” | “26” | “Diff: +6.54” |

Source: [van der Graaf et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_1_ESMO_BriefOralPres_V1.0_21-Sept-2026.pdf)

> “clinically meaningful improvement = +3.10”
> “Baseline was originally defined as the last assessment before randomization and was redefined post hoc to include PRO assessments completed on or before first dose.”
> “Results shown use this updated baseline definition and remained consistent with the primary week 12, 24, and 48 findings.”

Source: [van der Graaf et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_1_ESMO_BriefOralPres_V1.0_21-Sept-2026.pdf)

<a id="topic-3.1.1.8.4-7"></a>

##### PROMIS Physical Function at week 48, ESMO 2026 press release

> “On the PROMIS Physical Function measure, where higher scores indicate better function, the least-squares mean change from baseline was +3.90 with varegacestat vs. -3.04 with placebo at week 48.”

Source: [Immunome press release, ESMO 2026 data (2026)](https://investors.immunome.com/immunome-presents-additional-clinical-data-for-varegacestat-in-desmoid-tumors-at-esmo-2026/)

<a id="heading-3.1.1.8.5"></a>

#### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

##### Overall adverse event summary, ASCO 2026 abstract

> “Overall, 95% of adverse events (AEs) were Grade 1-2 and there were no Grade 5 AEs.”
> “Grade 3/4 AEs were reported in 57% of VAR pts and 17% of PBO pts.”
> “AEs led to dose reduction in 63 (80%) VAR pts and 7 (9%) PBO pts; 16 (20%) VAR pts and 5 (7%) PBO pts discontinued due to AEs.”
> “In the VAR arm, the most frequently reported AEs were diarrhea (82%), fatigue (44%), and rash (43%).”

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)

<a id="topic-3.1.1.8.5-2"></a>

##### Adverse events reported in 25% or more of either arm, ASCO 2026 presentation

| Adverse event (MedDRA preferred term), n (%) | Varegacestat any grade | Varegacestat grade 3+ | Placebo any grade | Placebo grade 3+ |
| --- | --- | --- | --- | --- |
| Any adverse event | “79 (100)” | “45 (57)” | “70 (91)” | “13 (17)” |
| Diarrhea | “65 (82)” | “8 (10.1)” | “21 (27)” | “0” |
| Fatigue | “35 (44)” | “1 (1.3)” | “18 (23)” | “2 (2.6)” |
| Rash | “34 (43)” | “2 (2.5)” | “9 (12)” | “0” |
| Nausea | “28 (35)” | “0” | “20 (26)” | “0” |
| Cough | “27 (34)” | “0” | “4 (5)” | “0” |
| Hypophosphatemia | “27 (34)” | “1 (1.3)” | “2 (3)” | “0” |
| Alopecia | “26 (33)” | “0” | “3 (4)” | “0” |
| Dry mouth | “24 (30)” | “0” | “5 (7)” | “0” |
| Hair color changes | “20 (25)” | “0” | “0” | “0” |
| Pruritus | “20 (25)” | “0” | “4 (5)” | “0” |
| Rash maculo-papular | “20 (25)” | “1 (1.3)” | “1 (1)” | “0” |

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

> “Reported in ≥25% in either arm”
> “MedDRA preferred terms”

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

<a id="topic-3.1.1.8.5-3"></a>

##### Most common treatment-emergent adverse events reported in 20% or more of either arm, ESMO 2026 safety poster

| Adverse event (MedDRA preferred term), n (%) | Varegacestat any grade | Varegacestat grade ≥3 | Placebo any grade | Placebo grade ≥3 |
| --- | --- | --- | --- | --- |
| Any adverse event | “79 (100)” | “45 (57)” | “70 (91)” | “13 (17)” |
| Diarrhea | “65 (82)” | “8 (10)” | “21 (27)” | “0” |
| Fatigue | “35 (44)” | “1 (1)” | “18 (23)” | “2 (2.6)” |
| Rash | “34 (43)” | “2 (3)” | “9 (12)” | “0” |
| Nausea | “28 (35)” | “0” | “20 (26)” | “0” |
| Cough | “27 (34)” | “0” | “4 (5)” | “0” |
| Hypophosphatemia | “27 (34)” | “1 (1)” | “2 (3)” | “0” |
| Alopecia | “26 (33)” | “0” | “3 (4)” | “0” |
| Dry mouth | “24 (30)” | “0” | “5 (7)” | “0” |
| Hair color changes | “20 (25)” | “0” | “0” | “0” |
| Pruritus | “20 (25)” | “0” | “4 (5)” | “0” |
| Rash maculo-papular | “20 (25)” | “1 (1)” | “1 (1)” | “0” |
| ALT increase | “18 (23)” | “3 (4)” | “4 (5)” | “0” |
| AST increase | “18 (23)” | “2 (3)” | “2 (3)” | “0” |
| Amenorrhea | “17 (22)” | “0” | “2 (3)” | “0” |
| Upper respiratory tract infection | “17 (22)” | “0” | “5 (7)” | “0” |
| Vomiting | “16 (20)” | “0” | “6 (8)” | “0” |

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

> “Reported in ≥20% in either arm”
> “Population: all participants who received ≥1 dose of study drug (i.e., the intention-to-treat population).”

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

<a id="topic-3.1.1.8.5-4"></a>

##### Frequently reported adverse events as grouped terms, with median time to first onset

| Adverse event, n (%) | Varegacestat all grades | Varegacestat median time to onset (days) | Varegacestat grade ≥3 | Placebo all grades | Placebo median time to onset (days) | Placebo grade ≥3 |
| --- | --- | --- | --- | --- | --- | --- |
| Diarrhea | “65 (82.3)” | “14.0” | “8 (10.1)” | “21 (27.3)” | “21.0” | “0” |
| Rash (grouped term) | “56 (70.9)” | “24.0” | “4 (5.1)” | “13 (16.9)” | “69.0” | “0” |
| Fatigue (grouped term) | “46 (58.2)” | “27.5” | “1 (1.3)” | “24 (31.2)” | “19.0” | “2 (2.6)” |
| Hair follicle AEs (grouped term) | “32 (40.5)” | “59.0” | “2 (2.5)” | “3 (3.9)” | “70.0” | “0” |
| Cough (grouped term) | “31 (39.2)” | “16.0” | “1 (1.3)” | “5 (6.5)” | “198.0” | “0” |
| Nausea | “28 (35.4)” | “8.0” | “0” | “20 (26.0)” | “7.5” | “0” |
| Hypophosphatemia | “27 (34.2)” | “29.0” | “1 (1.3)” | “2 (2.6)” | “49.5” | “0” |
| Upper respiratory infection (grouped term) | “27 (34.2)” | “46.0” | “0” | “6 (7.8)” | “136.5” | “0” |
| Dry mouth | “24 (30.4)” | “13.0” | “0” | “5 (6.5)” | “8.0” | “0” |
| Hair color changes | “20 (25.3)” | “60.5” | “0” | “0” | | “0” |
| Ovarian toxicity (grouped term; percentage of the whole population) | “20 (25.3)” | “56.5” | “0” | “2 (2.6)” | “41.5” | “0” |

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

> “denotes grouped terms comprising multiple clinically related MedDRA preferred terms”
> “calculated as a percentage of the whole population – see Ovarian Toxicity section for more details”

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

<a id="topic-3.1.1.8.5-5"></a>

##### Select adverse events of interest by grade, including squamous cell carcinoma and keratoacanthoma

| Adverse event of interest | Varegacestat grade 1 | Varegacestat grade 2 | Varegacestat grade 3 | Placebo grade 1 | Placebo grade 2 | Placebo grade 3 |
| --- | --- | --- | --- | --- | --- | --- |
| Diarrhea | “43.0%” | “29.1%” | “10.1%” | “23.4%” | “3.9%” | |
| Rash (grouped terms) | “36.7%” | “29.1%” | “5.1%” | “14.3%” | “2.6%” | |
| Ovarian toxicity | | “25.3%” | | | “2.6%” | |
| Squamous cell carcinoma and keratoacanthoma | “1.3%” | “6.3%” | “1.3%” | | | “1.3%” |
| Elevated liver enzymes (ALT or AST grade 2 or higher) | | “3.8%” | “3.8%” | | “2.6%” | |

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

> “Among these AEs, the most frequently reported were diarrhea and rash, which were primarily grade 1-2”
> “Defined as alanine aminotransferase or aspartate aminotransferase with grade ≥2 per Common Terminology Criteria for Adverse Events (CTCAE) v5.0”

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

<a id="topic-3.1.1.8.5-6"></a>

##### Serious adverse events and deaths

> “No deaths due to adverse events”
> “Serious adverse events: Varegacestat: 25 pts (32%) | Placebo: 7 pts (9%)”

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

> “There were no deaths on study”

Source: [Immunome topline call presentation (2025)](https://investors.immunome.com/wp-content/uploads/2025/12/Immunome-Topline-Call-Presentation-FINAL.pdf)

> “There were no deaths on study”

Source: [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf)

<a id="topic-3.1.1.8.5-7"></a>

##### Alopecia by grade

> “Of 26 patients reporting alopecia, 25 were Grade 1”

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

> “Of 26 varegacestat participants reporting alopecia, 25 had Grade 1 and one had Grade 2 attributed to another drug associated with alopecia”

Source: [Kasper et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_3_ESMO-2026_RINGSIDE-B_Topline-T2W_POS_final.pdf)

<a id="topic-3.1.1.8.5-8"></a>

##### Dose reductions, ASCO 2026 presentation

> “Varegacestat 80% | Placebo 9%”
> “Varegacestat 3.5 months | Placebo 5.6 months”
> “Most common reason: diarrhea 19%”

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

<a id="topic-3.1.1.8.5-9"></a>

##### Dose levels and time to first dose reduction or interruption

> “1.2 mg once daily”
> “0.9 mg once daily”
> “0.6 mg once daily”

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

| Measure | Varegacestat | Placebo |
| --- | --- | --- |
| Median time to first dose reduction to 0.9 mg | “to 0.9 mg (n=60): 3.7 (IQR 1.8, 8.3) months” | “to 0.9 mg (n=7): 5.6 (IQR 2.1, 16.1) months” |
| Median time to first dose reduction to 0.6 mg | “to 0.6 mg (n=36): 7.3 (IQR 3.0, 12.5) months” | “to 0.6 mg (n=2): 10.7 (IQR 4.9, 16.6) months” |
| Median time to first dose interruption | “Varegacestat (n=63): 2.5 (IQR 1.0, 5.7) months” | “Placebo (n=29): 3.4 (IQR 1.9, 7.3) months” |

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

<a id="topic-3.1.1.8.5-10"></a>

##### Adverse events leading to dose reduction

> “Dose Reduction”
> “Varegacestat 80% | Placebo 9%”

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

| Preferred term, n (%) | Varegacestat (n=79) | Placebo (n=77) |
| --- | --- | --- |
| Diarrhea | “15 (19.0)” | “0” |
| Fatigue | “7 (8.9)” | “1 (1.3)” |
| Rash | “7 (8.9)” | “0” |
| Rash maculo-papular | “6 (7.6)” | “0” |
| Folliculitis | “4 (5.1)” | “0” |
| Hidradenitis | “4 (5.1)” | “0” |
| ALT increased | “3 (3.8)” | “0” |
| Cough | “3 (3.8)” | “1 (1.3)” |

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

<a id="topic-3.1.1.8.5-11"></a>

##### Adverse events leading to dose interruption

> “Varegacestat 65% | Placebo 14%”

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

| Preferred term, n (%) | Varegacestat (n=79) | Placebo (n=77) |
| --- | --- | --- |
| Diarrhea | “9 (11.4)” | “1 (1.3)” |
| Fatigue | “6 (7.6)” | “0” |
| Rash | “6 (7.6)” | “0” |
| Vomiting | “5 (6.3)” | “1 (1.3)” |
| ALT increased | “4 (5.1)” | “2 (2.6)” |
| Pyrexia | “4 (5.1)” | “1 (1.3)” |

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

<a id="topic-3.1.1.8.5-12"></a>

##### Adverse events leading to discontinuation

> “Varegacestat 20% | Placebo 7%”

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

| Preferred term, n (%) | Varegacestat (n=79) | Placebo (n=77) |
| --- | --- | --- |
| Fatigue | “2 (2.5)” | “1 (1.3)” |
| Hidradenitis | “2 (2.5)” | “0” |
| Hyperthyroidism | “2 (2.5)” | “0” |

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

> “Varegacestat 20% | Placebo 7%”
> “Reasons varied with no events in >2.6%”

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

> “Discontinuation Due to AEs: Varegacestat 20% | Placebo 6%”
> “Reasons varied with no single event in >2 participants”

Source: [Kasper et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_3_ESMO-2026_RINGSIDE-B_Topline-T2W_POS_final.pdf)

<a id="topic-3.1.1.8.5-13"></a>

##### Ovarian toxicity in premenopausal women

> “Ovarian toxicity occurred in 20/36 (56%) premenopausal women on VAR, resolved in 11/20 (55%), and did not lead to dose interruption or drug withdrawal.”

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)

> “A known class effect of GSI”
> “Varegacestat 56% | Placebo 5%”
> “Resolved in 55% of those who reported it”
> “No discontinuations for ovarian toxicity”
> “Ovarian toxicity includes the MedDRA preferred terms amenorrhea, premature menopause, menopause, ovarian failure”

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

> “55.6% of premenopausal women experienced ovarian toxicity”

Source: [Immunome topline call presentation (2025)](https://investors.immunome.com/wp-content/uploads/2025/12/Immunome-Topline-Call-Presentation-FINAL.pdf)

> “20 of 36 (56%) of premenopausal women experienced ovarian toxicity, which resolved in 11 of 20 patients (55%)”

Source: [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf)

<a id="topic-3.1.1.8.5-14"></a>

##### Ovarian toxicity resolution by treatment disposition

> “Resolution by treatment disposition – data cutoff Oct 7, 2025”
> “20 of 36 premenopausal women with ovarian toxicity (56%)”
> “8 off varegacestat, follow-up available”
> “OT resolved in 8 (100%)”
> “10 ongoing varegacestat”
> “OT resolved in 3 (30%)”
> “OT unresolved in 7 (70%)”
> “2 off study, no follow-up available”
> “No women discontinued varegacestat due to ovarian toxicity”
> “Ovarian toxicity resolved in all participants with follow-up data after stopping treatment”

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

<a id="topic-3.1.1.8.5-15"></a>

##### Most common adverse events by arm, rounded to whole percentages

> “The most common adverse events for participants in the treatment arm as opposed to the placebo arm were diarrhea (82% vs. 27%), fatigue (44% vs. 23%), rash (43% vs. 12%), nausea (35% vs. 26%) and cough (34% vs. 5%).”
> “Most (95%) adverse events were grade 1 or 2.”
> “Dose reductions due to treatment-emergent adverse events occurred in 80% of patients treated with varegacestat vs. 9% with placebo.”
> “Treatment discontinuations due to adverse events occurred in 20% of patients treated with varegacestat vs. 7% with placebo.”

Source: [Immunome press release, RINGSIDE data at ASCO 2026 (2026)](https://investors.immunome.com/immunome-announces-detailed-phase-3-ringside-data-for-varegacestat-in-adults-with-progressing-desmoid-tumors-at-the-2026-asco-annual-meeting/)

<a id="heading-3.1.1.9"></a>

### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

#### Summary

- Part B results are available only as an ASCO 2026 meeting abstract and oral presentation, ESMO 2026 presentations, and Immunome press releases and investor presentations. The abstract states that it “does not include a full text component”. The ClinicalTrials.gov record (primary completion December 3, 2025; status active, not recruiting) lists no posted results, and no registry protocol or statistical analysis plan is available for comparison with the reported analyses. The study was “sponsored/funded by Immunome and Ayala Pharmaceuticals, Inc.”.
- The comparator is placebo. No trial has compared varegacestat with nirogacestat, the approved gamma secretase inhibitor; Immunome's cross-trial response rate chart states that “no head-to-head clinical trial has been conducted”.
- Crossover to the open-label extension was allowed from either arm at progression, and the open-label extension is ongoing. Median exposure was 20.3 months with varegacestat and 11.1 months with placebo, so cumulative adverse event frequencies are compared over unequal exposure.
- At the October 7, 2025 data cutoff, 7 of 79 varegacestat participants and 29 of 77 placebo participants had a PFS event; median PFS was not estimable and median duration of response was not reached with varegacestat, which limits the precision of the hazard ratio and of the 2-year landmark estimates.
- The ASCO presentation labels a “Post-hoc subgroup analysis to evaluate patients with poor prognosis”; the subgroups shown include age 30 years or younger, CTNNB1 mutation, and baseline tumor size above 10 cm, and the abstract states only that PFS “consistently favored VAR in all subgroups analyzed”.
- Baseline imbalances include intra-abdominal target tumors (24.1% with varegacestat and 36.4% with placebo), any prior therapy (65.8% and 77.9%), and prior surgery (30.4% and 42.9%); the placebo arm's target tumor size range extends to 666.3 mm.
- Dose reductions due to adverse events occurred in 80% of varegacestat participants (to 0.9 mg in 60 and to 0.6 mg in 36), and dose interruptions in 65%. The efficacy results therefore reflect a 1.2 mg starting dose with frequent reduction, and the dose intensity actually delivered has not been reported.
- The symptom, pain domain, and physical function analyses are exploratory, with nominal p values. Completion declined over time: at week 48, pain and symptom data were available for 37 varegacestat and 27 placebo participants, against 52 and 55 at week 12. The PROMIS Physical Function baseline was “redefined post hoc”. Characteristic adverse events (diarrhea in 82% versus 27%, alopecia in 33% versus 4%, hair color changes in 25% versus 0%) may have allowed participants to infer their assignment, which could bias patient-reported outcomes in a double-blind trial.
- Figures differ between sources. The PFS hazard ratio's 95% CI is 0.07 to 0.38 in the abstract and slides and 0.071 to 0.375 in Immunome releases. ORR is 55.7% versus 9.1% in the abstract and slides and 56% versus 9% in releases. Placebo discontinuation due to adverse events is 7% in the abstract, ASCO slides, and safety poster and 6% in the primary results poster. Premenopausal women are 45.6% of the varegacestat arm in one table and 67.9% of its female participants in another. Rash is 43% as a preferred term and 70.9% as a grouped term. Death is reported as “No deaths due to adverse events” in the ESMO safety poster and as “There were no deaths on study” in the investor presentations. Ovarian toxicity resolved in 55% overall but in all 8 participants with follow-up off treatment. Week 48 PROMIS Physical Function is reported as +3.90 versus −3.04 in the ESMO press release, while the presentation, using the redefined baseline, reports a difference of +6.54.

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506); [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf); [Kasper et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_3_ESMO-2026_RINGSIDE-B_Topline-T2W_POS_final.pdf); [van der Graaf et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_1_ESMO_BriefOralPres_V1.0_21-Sept-2026.pdf); [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf); [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282); [Immunome press release, RINGSIDE topline results (2025)](https://investors.immunome.com/immunome-announces-positive-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors/); [Immunome press release, RINGSIDE data at ASCO 2026 (2026)](https://investors.immunome.com/immunome-announces-detailed-phase-3-ringside-data-for-varegacestat-in-adults-with-progressing-desmoid-tumors-at-the-2026-asco-annual-meeting/); [Immunome press release, ESMO 2026 data (2026)](https://investors.immunome.com/immunome-presents-additional-clinical-data-for-varegacestat-in-desmoid-tumors-at-esmo-2026/); [Immunome topline call presentation (2025)](https://investors.immunome.com/wp-content/uploads/2025/12/Immunome-Topline-Call-Presentation-FINAL.pdf); [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf)

## Related pages
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors.md)
- [Varegacestat (AL102) in Desmoid tumors: Terms and abbreviations](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations.md)
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary.md)
- [Varegacestat (AL102) in Desmoid tumors: Product information and disease description](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description.md)
- [Varegacestat (AL102) in Desmoid tumors: Clinical evidence](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence.md)
- [Varegacestat (AL102) in Desmoid tumors: Economic information and modeling report](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics.md)
- [Varegacestat (AL102) in Desmoid tumors: References](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references.md)
